Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Source link
Similar Posts
We See Further Recovery For Lantronix
We See Further Recovery For Lantronix Source link
Early Q3 GDP Tracking
by Calculated Risk on 8/08/2025 11:41:00 AM From BofA: Next week, we will initiate our 3Q GDP tracker … [August 8th comment]emphasis added From Goldman: [W]e boosted our Q3 GDP tracking estimate by 0.2pp to +1.2% (quarter-over-quarter annualized). Our Q3 domestic final sales estimate stands at -0.1%. [August 7th estimate] And from the Atlanta Fed:…
2 No-Brainer Growth Stocks to Buy Right Now for Less Than $500
There’s no question that there’s been a significant divergence in stocks on the TSX in recent months. Some companies have been performing extremely well, while others continue to trade cheaply. However, with interest rates widely expected to continue declining, many of these discounts won’t last much longer. So, if you’re looking for high-quality growth stocks…
Matador Resources Insiders Keep Buying Its Stock, Should You?
Key Points Matador Resources is a diversified mid-cap energy play that is growing and paying dividends. Analysts are leading to the high-end range, expecting at least a 50% upside at consensus. Insiders are buying the stock, and institutional support is robust. Matador Resources (NYSE: MTDR) is an attractive mid-cap player in energy and growth because…
Last day to buy shares of 13 companies to qualify for dividends as Aug 27 record date approaches
Investors looking to earn dividends from a range of listed companies should note that Tuesday, August 26, is the last day to purchase shares to be eligible for the payouts. These companies have set Thursday as the record date, which will determine shareholders’ entitlement to dividend distributions. Among the prominent names, Procter & Gamble Hygiene…
